AbCellera Biologics Inc. (ABCL) — SEC Financial Statements & Analysis

AbCellera Biologics Inc. (ABCL) is a pharmaceutical preparations company, incorporated in A1. AbCellera Biologics Inc. trades on Nasdaq as: ABCL. AbCellera Biologics Inc. (ABCL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, AbCellera Biologics Inc. carries a market cap of $2.40B, a P/E ratio of -14.57x, a P/B ratio of 2.68x, a P/S ratio of 36.25x, an enterprise value of $2.25B, and an EV/EBITDA multiple of -11.21x. On profitability, it posts an operating margin of -340.25%, a net margin of -248.82%, a Return on Equity (ROE) of -17.30%, a Return on Assets (ROA) of -12.15%, and a Return on Invested Capital (ROIC) of -22.94%. Per share, it reports EPS of $-0.54, diluted EPS of $-0.54, free cash flow per share of $-0.39, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 101.29% year-over-year, net income growth of -0.61% year-over-year, and EPS growth of -2.90% year-over-year. On the balance sheet, it maintains a current ratio of 12.77x, a quick ratio of 12.77x, working capital of $626.04M, a debt-to-equity ratio of 0.46x, a debt ratio of 0.31, an interest coverage ratio of -5360.81x, free cash flow of $-119.67M (TTM), and net debt of $-145.06M. Figures sourced from SEC EDGAR.

Market Cap

$2.40B

P/E TTM

-14.57x

EPS TTM

$-0.54

P/B TTM

2.68x

ROE TTM

-17.30%

ROA TTM

-12.15%

Debt To Equity

0.46x

Free Cash Flow TTM

$-119.67M

Net Revenue TTM Growth 1Y

101.29%

Data as of 2026-06-30 · Source: SEC EDGAR